NEW YORK, NY / ACCESSWIRE / January 30, 2017 / A combination of corporate earnings and strong performances by the manufacturers and miners helped U.S. markets post strong weekly gains during President Trump’s first week in office. The Dow Jones Industrial Average declined 0.04 percent to close at 20,093.78, up 1.33 percent for the week, while the S&P 500 Index declined 0.09 percent to close at 2,294.69, up 1.01 percent for the week. The Nasdaq rose 0.10 percent to close at a new record 5,660.78, posting a weekly gain of 1.88 percent.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

As of 104 companies in the S&P 500 Index reporting earnings through Wednesday morning approximately 70 percent have topped expectations, according to data from Thomson Reuters I/B/E/S. Earnings in the fourth quarter are forecasted to show a growth of 6.8 percent, which would be the largest growth rate seen in two years.

Starbucks Corporation (NASDAQ: SBUX)

Get Your Up-To-Date Starbucks Research
Report Click Here

Starbucks’ shares declined 4.00 percent to close at $56.12 a share Friday. The stock traded between $55.65 and $56.59 on volume of 28.88 million shares traded. The company reported adjusted earnings of $0.52 per share on revenues of $5.73 billion for the first quarter of fiscal 2017, which compared to the Street’s estimates of adjusted earnings of $0.52 per share and revenues of $5.85 billion. Starbucks reported same-store sales growth of 3 percent for the fiscal first quarter, which fell short of analysts’ estimates of 3.8 percent. The company has attributed some of the drop in same-store sales to mobile pay and ordering.

“We are pleased with the record Q1 financial and operating results we announced today, particularly given that the results were delivered in the face of a challenging environment for restaurant retailers overall,” Scott Maw, CFO of Starbucks said in their earnings release.

Colgate-Palmolive Company (NYSE: CL)

Get Your Up-To-Date Colgate-Palmolive
Research Report Click Here

Colgate-Palmolive’s shares declined 5.22 percent to close at $64.68 a share Friday. The stock traded between $63.43 and $65.05 on volume of 14.87 million shares traded. The company reported a net income of $606 million, or $0.68 per share, for the fourth quarter of 2016, compared to a loss of $458 million, or a loss of $0.51 per share, for the fourth quarter of 2015. Sales totaled $3.72 billion for the fourth quarter, which was a decline from $3.9 billion a year ago and below consensus analysts’ estimates of $3.89 billion, according to FactSet. Organic sales growth at the company was 1.5 percent for the quarter, with a 2.5 percent rise in price and 1 percent decline in volume. Considering current exchange rate, the company expects a low single-digit growth in net sales and per share earnings in the year 2017.

“As we look ahead, uncertainty in global markets and foreign exchange volatility remain challenging, which sees us redoubling our focus on profitable growth. While based on current spot rates, we expect a low-single-digit net sales increase for 2017, we anticipate another year of solid organic sales growth driven by a full new product pipeline, engaging marketing programs and strong advertising support,” commented Ian Cook, Chairman, President and Chief Executive Officer.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453786

TORONTO, ON / ACCESSWIRE / January 30, 2017 / Icon Exploration Inc. (TSX-V: IEX.H) (“Icon” or “the Company”) is pleased to provide an update and overview of the Company’s goals and growth plans for 2017.

Icon’s Board and Management continues to rigorously investigate various opportunities in several industries and has decided to focus on the mining sector to take advantage of low cost acquisition opportunities. Both metal prices and investor interest in mining has fluctuated significantly during 2016. Despite the market fluctuations, Icon expects that several new projects will emerge as potential acquisition candidates. Over the next quarter Management expects to shortlist its proposed top mining acquisition opportunities for Icon and establish what it believes will be the optimal structure to complete such acquisitions (whether by option agreement, asset acquisition, joint venture or share purchase of any entity which holds the mining assets). Along with the mining acquisitions the Company will prudently explore funding partners to secure the assets and will draw on geological talent to complement the acquisitions and the Company.

Rob Fia CEO & Director: “We are excited to position Icon to capitalize on what looks to be a bull market in precious and base metals and hope to acquire an extensive mining property portfolio diversified across various commodities while actively funding the Company. We would like to thank our partners and shareholders for their patience and support and look forward to the potential to make a transformative mining acquisition during 2017.”

The Company will provide shareholders with updates on these opportunities when material information becomes available.

Icon Exploration Inc.
Rob Fia, CEO & Director

For further information:

Email: rfia@kingsdalecapital.com
Tel: 416-867-2353
Fax: 416-867-4566

Forward-looking information

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events or the Company’s future performance and include potential mining acquisitions as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company’s potential mining acquisitions may prove to be unsuccessful and the Company may be unable to complete any potential mining acquisition. Further, the Company may not complete any potential mining acquisition on the schedule it expects to complete as described in this news release or attract capital in the future to finance the Company. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES

SOURCE: Icon Exploration Inc.

ReleaseID: 453804

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / Casino stocks could look to benefit from the recent surge in gaming revenues from Macau. Data from Macau’s Gaming Inspection and Coordination Bureau show that gross gaming revenues rose 8 percent year-over-year to 19.8 billion patacas ($2.48 billion) in December, this follows a 14.4 percent year-over-year increase in November. Total casino revenues for the full year 2016 declined 3.3 percent to 223.2 billion patacas, a substantial improvement from the 34.3 percent decline experienced in 2015. That number is expected to continue to improve as gambling revenues are forecasted to grow by 7 percent in 2017, according to analysts surveyed by Bloomberg.

Register with us now
for your free membership and gain access to our latest research reports at: RDInvesting.com

Additionally, casino operators will now have an opportunity for new revenues stream in Japan. After many delays, the Japanese government on December 15th, 2016 passed a law legalizing casinos. The opening of just two casinos initially could see Japan’s gaming revenues total over $10 billion, with that number eventually growing to $25 billion, according to a recent report from CLSA.

Las Vegas Sands Corp. (NYSE: LVS)

Get Your Up-To-Date Las Vegas Sands
Research Report Click Here

Las Vegas Sands’ shares gained 1.74 percent to close at $53.32 a share Friday. The stock traded between $52.70 and $53.78 on volume of 8.06 million shares traded. The company reported a GAAP net income of $509 million or $0.64 a share for the fourth quarter of 2016, an increase of 9.2 percent when compared to a GAAP net income of $466 million or $0.59 a share in the fourth quarter of 2015. Net revenues were $3.08 billion for the fourth quarter of 2016, an increase of 7.4 percent when compared to a year ago. Consensus analysts’ estimates have called for GAAP net income of $0.66 per share on revenue of $3.11 billion, according to Thomson Reuters I/B/E/S.

Wynn Resorts, Limited (NASDAQ: WYNN)

Get Your Up-To-Date Wynn Resorts Research
Report Click Here

Wynn Resorts’ shares spiked 7.94 percent to close at $103.08 a share Friday. The stock traded between $101.00 and $104.05 on volume of 7.97 million shares traded. The company reported net revenues were $1.30 billion for the fourth quarter of 2016, an increase of 37.3 percent when compared to $946.9 million in the fourth quarter of 2015. The jump in revenues was primarily attributed to the company’s Macau property, Wynn Palace which was opened on August 22nd. The Wynn Palace provided net revenues of $418.7 million in the fourth quarter of 2016, revenue from its casino operations were $373.2 million. Reported adjusted earnings were $51.0 million or $0.50 per share, against adjusted earnings of $104.1 million or $1.03 per share in same quarter last year. Analysts’ expectations had called for adjusted earnings of $0.85 a share on revenues of $1.26 billion, according to Thomson Reuters.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 453778

CHATSWORTH, CA / ACCESSWIRE / January 30, 2017 / Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (BERLIN: WTC) (STUT: WTC) (FRANKFURT: WTC), received a new purchase order from Desmet Ballestra Group, CTi’s strategic partner and licensee of the company’s vegetable oil refining technology since 2010. CTi Nano Reactor™ systems are to be installed for use in soybean oil refineries in Thailand ~700 and ~400 metric tonnes per day (MTPD). The company anticipates the systems installations to be completed in the company’s fiscal 4th Quarter 2017 and receive approximately $500,000 in revenue.

Cavitation Technologies, Inc COO/CFO N.D.Voloshin said, “For the past 6 years, our continuous R&D and Business relationship with Desmet Ballestra has been steadily growing and through a dedicated and focused approach to integrate CTi’s nano technology to customers worldwide, this latest order comes from the soybean oil refinery in Thailand, our company’s first system installation in the country.”

About CTi:

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algal oil extraction, alcoholic beverage enhancement and water treatment. As an add-on to its existing neutralization systems, the company’s patented Nano Reactor™ allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield. http://www.ctinanotech.com/

About Desmet Ballestra Group:

The Desmet Ballestra Group provides engineering and supply of plants and equipment for the following industries worldwide:

Oils and Fats and Animal Feed

Detergents, Surfactants and related Chemicals

Oleochemical and Biodiesel

Desmet Ballestra’s R&D Team is composed of professionals specialized in Oils and Fats, oleochemicals and chemical processes, using the most comprehensive set of technological resources and equipment. Controlled by Financière DSBG, a holding company based in Paris, France, the Desmet Ballestra Group is present in all major market areas of the world through its integrated business units located in Northern and Central America (USA, Mexico), South America (Argentina, Brazil, Colombia), Asia & Far East (PR China, Singapore, Malaysia), India and Europe (Belgium, Turkey, Russia, Spain).

Forward Looking Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder’s value. These forward-looking statements are based largely on the Company’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company’s control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment, the continued success of our relationship with Desmet and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

Investment Relations

Cavitation Technologies, Inc.
Jessica Steidinger

Jessica@ctinanotech.com
Phone: (818) 718-0905

SOURCE: Cavitation Technologies, Inc.

ReleaseID: 453766

NEW YORK, NY / ACCESSWIRE / January 30, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) today published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Bacha reflects on DelMar’s recently announced Phase 2 trial with MD Anderson Cancer Center for MGMT-unmethylated glioblastoma multiforme (GBM) patients. He writes that this new trial is a keystone in the Company’s strategy to expand the development of VAL-083 to “have the greatest disease impact, the greatest benefit to patients, and, ultimately, the greatest benefit to shareholder value.” Read the full blog post from Mr. Bacha on TheChairmansBlog.com (http://www.thechairmansblog.com/delmar-pharmaceuticals/jeffrey-bacha/optimism-and-opportunity-as-we-initiate-clinical-trials-for-mgmt-unmethylated-gbm-patients-at-md-anderson-2/).

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment (www.thechairmansblog.com).

SOURCE: The Chairman’s Blog

ReleaseID: 453802

MONTCLAIR, NJ / ACCESSWIRE / January 30, 2017 / Nexus BioPharma, Inc., (OTC PINK: NEXS), a company specializing in the development of a weight loss drug therapy, announced today that it has been selected to become a resident company at the Johnson & Johnson Innovation, JLABS (JLABS) facility at the Texas Medical Center in Houston, Texas (JLABS @ TMCx). The Company will relocate its headquarters to Houston as of February 1, 2017.

Warren C. Lau, President and CEO of Nexus stated, “We are pleased to have passed the rigorous vetting and screening process for selection. The availability of facilities and equipment, the collegial atmosphere created by the concentration of entrepreneurial and scientific talent, and especially the access to expertise and mentoring makes this a very special opportunity for Nexus.”

About Nexus BioPharma, Inc. www.nexusbiopharma.com

Nexus BioPharma, Inc. is developing a class of new molecular entities for weight loss that work differently than any currently available prescription drugs. Their mechanism of action is believed to alter the body’s metabolism to increase the burning of fat by activating the AMPK metabolic pathway, the same pathway activated by intense physical exercise.

The underlying biochemistry was described in an article in the journal Cell Metabolism by Claire C. Bastie, and Jeffrey E. Pessin, entitled “Fyn-Dependent Regulation of Energy Expenditure and Body Weight Is Mediated by Tyrosine Phosphorylation of LKB1”. Cell Metab. 2010 Feb 3;11(2):113-24

In completed pre-clinical animal studies of the pharmaceutical activation of this pathway, test subjects showed reduced fat mass with no loss of lean muscle mass, plus a higher rate of energy expenditure, increased insulin sensitivity, increased fatty acid oxidation, improved plasma and tissue triglyceride levels, with lower cholesterol. Upon translation of this pharmaceutical activation to humans, these effects are expected to have a significant impact on obesity and diabetes.

Using the most advanced high throughput screening technology, Nexus BioPharma has identified small molecule compounds in a number of discrete chemical structure families that can efficiently activate the AMPK pathway. The Company has filed for intellectual property protection on a selection of compounds in a number of discrete chemical backbones. The Company’s goal is to advance to pre-IND trials in preparation for first in human trials with their new molecular class of compounds.

Cautionary Statement Regarding Forward-Looking Information

This press release may contain certain “forward-looking statements” relating to the business of Nexus BioPharma, and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the impact of the proceeds from the private placement on the Company’s short term business and operations,; the general ability of the Company to achieve its commercial objectives, including the ability of the Company to sustain growth; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Lara Cely
lara.cely@nexusbiopharma.com
917-524-6107

SOURCE: Nexus BioPharma, Inc.

ReleaseID: 453746

DUBUQUE, IA / ACCESSWIRE / January 30, 2017 / Heartland Financial USA, Inc. (NASDAQ: HTLF) will host a live webcast and conference call to discuss the results of the fourth quarter 2016, to be held Monday, January 30, 2017 at 5:00 PM Eastern Time.

Live Event Information

To participate, connect approximately 5 to 10 minutes before the beginning of the event.

Date, Time: January 30, 2017 at 5:00 PM ET
Toll Free: 877-407-0782
Live Webcast: www.investorcalendar.com/IC/CEPage.asp?ID=175515 or http://www.htlf.com

About Heartland Financial USA, Inc.

Heartland Financial USA, Inc. is a diversified financial services company with assets exceeding $8 billion. The company provides banking, mortgage, private client, investment, insurance and consumer finance services to individuals and businesses. Heartland currently has 108 banking locations serving 85 communities in Iowa, Illinois, Wisconsin, New Mexico, Arizona, Montana, Colorado, Minnesota, Kansas, Missouri, Texas and California. Additional information about Heartland Financial USA, Inc. is available at www.htlf.com.

SOURCE: Investor Network

ReleaseID: 453798

POMPANO BEACH, FL / ACCESSWIRE / January 30, 2017 / Shareholders who missed DS Healthcare’s call on January 27, 2017 that covered latest updates and strategic initiatives for 2017 may access the replay at the following link: http://www.dslaboratories.com/investornews

About DS Healthcare Group

DS Healthcare Group Inc. is a leader in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, and pharmacies. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects.

For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com.

SOURCE: DS Healthcare Group

ReleaseID: 453800

CARLSBAD, CA / ACCESSWIRE / January 30, 2017 / ISO International, LLC (“Isodiol“) is proud to announce that its proprietary nano-amplified cannabinoids fueled the completion of a definitive equity agreement by Laguna Blends (CNSX: LAG) (OTC PINK: LAGBF) (FSE: LB6A.F) with the Company’s joint venture, Carlsbad Naturals, LLC.

Carlsbad Naturals, LLC, owns and operates the brand name CBD Naturals, a unique bottled water consumer product that is widely recognized in the U.S. hemp-infused bottled water market. CBD Naturals alkaline bottled water ingredients include nano-amplified cannabinoids from Isodiol plus vitamins and antioxidants.

Laguna Blends, a Canadian headquartered company, markets and distributes hemp-based products. Laguna Blends sales expansion of CBD Naturals will be through its Club 8 online marketplace and via its business-to-business (B2B) channels in the U.S. and Canada.

Jared Berry, CEO of Isodiol, states, “Everyone at Isodiol is excited and proud to supply our proprietary nano-amplified cannabinoids to Laguna Blends through CBD Naturals bottled water. With the completion of the definitive agreement between Laguna Blends and Carlsbad Naturals, the focus is now on expanding distribution of CBD Naturals’ unique hemp cannabinoid-infused bottled water in both the U.S. and Canadian bottled water markets. Isodiol feels that the addition of nano-amplified cannabinoids to existing consumer products will create new market opportunities. Laguna Blends and CBD Naturals is a prime example.”

Ray Grimm, President & CEO of Laguna Blends, states, “The partnership with Carlsbad Naturals firmly solidifies Laguna Blends as a unique player in the multibillion dollar bottled water and functional beverage industry. Carlsbad Naturals CBD water was formulated with the sole purpose of creating a high alkaline water with the added benefits. Many believe this to be the next evolution in the water industry, providing unique health benefits due to the proprietary nanotechnology. Carlsbad Naturals CBD water provides antioxidants at the cellular level along with providing cellular hydration and energy. Laguna Blends is currently in discussions with Carlsbad Naturals regarding further business opportunities including but not limited to the acquisition of controlling interest.”

Terms of the definitive equity agreement are such that Laguna Blends has up to 75 days to acquire a 19% equity stake in Carlsbad Naturals. Laguna Blends will initially purchase nineteen percent (19%) equity interest in Carlsbad Naturals for a one-time payment of $250,000 USD paid for in cash plus $546,000 paid for in Laguna Blends’ common shares for a total purchase price of $796,000.00 USD. Laguna Blends is currently in discussions with Carlsbad Naturals about acquiring additional equity interest, for majority control.

The common shares issued for the initial 19% are subject to lock up and or leak out provisions whereby the first 1/12 of the common shares will be released 4 months and a day after issuance. 1/12 will be issued every subsequent month thereafter.

Charles Vest, VP of Sales of Laguna Blends, Inc.’s new hemp and CBD on-line marketplace “Club 8” said, “According to new data from Arcview Market Research, cannabis consumers in North America spent a combined $53 billion in cannabis consumables in 2016. The legal supply of cannabis product increases in North America because several US states have recently joined the list of legalizers while at the same time lawmakers are expected to begin the process of recreational legalization in Canada later this year. The estimated $53 billion in sales is more than was generated by McDonald’s and Starbucks combined in 2016.”

Vest adds, “The high amount of existing consumers differentiates cannabis from other major consumer-market investment opportunities in history. There is a huge demand for clean cannabis products in our industry today. We just need to move demand for an already widely-popular product into safe and legal channels. Experts see the biggest growth in sectors like edibles and concentrates. It is much easier and safer to buy these products from a trusted retailer than to make them at home. Not only Carlsbad Naturals’ nano-amplified CBD water but all of our current and upcoming products in ‘Club 8’ will benefit from this massive and unstoppable growth trend.”

For more information on nano-amplified cannabinoids, visit
Isodiol’s website and blog page. For manufacturers interested in adding nano-amplified cannabinoids to new or existing products, contact media@isodiol.com

About Laguna Blends, Inc.

Laguna Blends Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) is engaged in development, sales, marketing and distribution of hemp based products and solutions. Laguana specializes in identifying emerging trends and opportunities such as cannabidiol (CBD), one of the most useful compounds found in the hemp plant.

Laguna is currently seeking joint ventures and acquisitions to expand its portfolio in the hemp and cannabinoid markets. To learn more, visit www.LagunaBlendsInc.com, Facebook and YouTube.

About Isodiol:

Isodiol and its team of collaborators are a group of companies that together, grow & harvest hemp on an industrial scale, and then process it to extract the non-psychotropic cannabinoids to the highest available purity for worldwide distribution. By utilizing one of the world’s largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high-grade, non-psychotropic cannabinoids.

Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due to our products.
To follow Isodiol online, visit the Company’s website at http://www.isodiol.com, Facebook, Instagram, and Twitter.

FORWARD-LOOKING DISCLAIMER

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported.
The statements in this news release are made as of the date of this release.

LEGAL DISCLOSURE

Isodiol does not sell or distribute any products that are in violation of the
United States Controlled Substances Act (US.CSA). Cannabidiol is a natural
element of industrial hemp. Isodiol’s products are not intended to cure, treat
or mitigate any disease states.

SOURCE: Isodiol

ReleaseID: 453777